Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence

Trial Profile

Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms ADRESU
  • Most Recent Events

    • 12 Jun 2017 Long term safety data from this trial published in a Cytori Therapeutics Media Release.
    • 12 Jun 2017 According to a Cytori Therapeutics media release, thsi study published in June 2017 edition of Surgery.
    • 14 Dec 2016 According to a Cytori Therapeutics media release, 50% patients has been enrolled and treated in this trial. Full enrollment is anticipated in mid-2017. This trial is based on pilot trial data published in the International Journal of Urology in 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top